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The dried leaves of Ilex paraguariensis, also known as yerba mate or chimarrão, are used to produce 
infusions consumed by over 1 million people worldwide, being a traditional drink in several South 
American countries, particularly, Argentina, Brazil, Uruguay, and Paraguay. The positive effects of 
I. paraguariensis in obesity have been described and observed in some clinical trials both in animals and 
in humans. The main goal of this work was to perform a systematic review, complying with the PRISMA 
(Preferred Reported Items for Systematic Reviews and Meta-Analysis) recommendations, followed by 
a meta-analysis and Trial Sequential Analysis (TSA), to summarize the results of the recent clinical 
trials, clarifying the anti-obesity potential of I. paraguariensis. The search for this systematic review 
was performed on several electronic databases (Pubmed, Web of Science, Scopus, SciELO and Cochrane 
Library) in July 2017. A total of 22 clinical trials were considered for the quantitative synthesis of the 
data, totalizing 726 patients enrolled. In conclusion, this systematic review demonstrated the positive 
effects of I. paraguariensis consumption on the reduction of body weight, body mass index (BMI), and 
waist circumference of patients, showing its anti-obesity potential.
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INTRODUCTION
The dried leaves of Ilex paraguariensis, also 
known as yerba mate or chimarrão, are used to produce 
infusions consumed by over 1 million people worldwide, 
being a traditional drink in several South American 
countries, particularly, Argentina, Brazil, Uruguay, 
and Paraguay (Kim et al., 2015). More recently, the 
aqueous preparations of I. paraguariensis have also been 
consumed in North America and Europe (Kim et al., 
2015). The dried and minced leaves of I. paraguariensis 
are used to make brewed tea, which is often used both as a 
source of caffeine, but also as a therapeutic agent because 
of its pharmacological properties (Bracesco et al., 2011). 
The concentration of caffeine varies among the different 
types of tea (green tea: 130 mg/L; white tea: 140 mg/L; 
black tea: 89 mg/L) and coffee (70 mg/L), being the 
infusion of I. paraguariensis a great source of this 
compound (40 mg/L) (Rostagno et al., 2011).
The recent interest in I. paraguariensis is linked to 
its high content of phytochemicals and the peculiarity of 
its phenolic profile, characterized by the wealth in mono 
and dicaffeoylquinic acids, known for their biological 
activities (Cardozo Junior, Morand, 2016). It has also been 
shown that infusions of I. paraguariensis increase the 
antioxidant protection of plasma and cholesterol particles 
against ex vivo copper-mediated lipid peroxidation in 
humans, together with the improvement in the plasma 
lipid profile of normolipidemic and healthy dyslipidemic 
individuals (Boaventura et al., 2012; Morais et al., 2009). 
Furthermore, the consumption of I. paraguariensis 
beverages, seems to be related to an improvement of 
glycemic control on pre-diabetic subjects (Klein et al., 
2011). The positive effects of I. paraguariensis in obesity 
have been observed in some clinical trials both in animals 
and in humans (Pontilho et al., 2015; Gambero, Ribeiro, 
2015; Kim et al., 2012). 
Overall, 23.2% of the world’s adult population 
in 2005 was overweight, with 9.8% being considered 
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obese (Kim et al., 2012). The estimated total number of 
overweight and obese adults in 2008 was 1500 million and 
500 million, respectively (Kim et al., 2012). Moreover, 
in 2016, more than 1.9 billion adults, 18 years and older, 
were overweight, being 650 million of these considered 
obese (WHO, 2018). Additionally, 39% of adults aged 
18 years and over were overweight in 2016, and 13% were 
obese (WHO, 2018). Since the prevalence of obesity is a 
major public health concern, due to all the weight-related 
diseases that result in significant morbidity and mortality, 
and reduced quality of life, it is important to search for new 
strategies to help obese people reducing their body weight 
(Gambero, Ribeiro, 2015). I. paraguariensis appears as 
a potential new natural approach to treat obesity, being 
observed that I. paraguariensis modulates the expression of 
genes that are changed in the obese state and restores them 
to normal levels of expression (Gambero, Ribeiro, 2015). 
Despite the current research focused on the bioactive 
properties of I. paraguariensis, which has led to an increase 
in clinical trials in humans, contradictory results were 
frequently reported. Taking this context into consideration, 
the main goal of this work was to perform a systematic 
review, complying with the PRISMA (Preferred Reported 
Items for Systematic Reviews and Meta-Analysis) 
recommendations, followed by a meta-analysis and Trial 
Sequential Analysis (TSA), to summarize the results of the 
recent clinical trials, clarifying the anti-obesity potential 
of I. paraguariensis.
MATERIAL AND METHODS
Search strategy, inclusion criteria and study 
selection
The search for this systematic review was performed 
on several electronic databases (Pubmed, Web of Science, 
Scopus, SciELO and Cochrane Library) in July 2017. 
The databases were queried using the Boolean operator 
tools, with the following strategy: (Ilex paraguariensis OR 
yerba mate OR yerba maté OR chimarrão) AND (clinical 
trial OR trial) AND human. The list of references of the 
articles reviewed were also checked to find additional 
studies. Moreover, several academic theses of the authors 
of some articles were also found (Google Scholar) and 
were used to complement the gathering of the results. 
Following the PRISMA recommendations (Moher et al., 
2015), titles and abstracts of records retrieved were initially 
screened and the full texts of those considered relevant 
were then downloaded and analysed in detail. Two authors 
independently conducted the literature selection process, 
with a third being consulted in case of discrepancies. To be 
included in this systematic review, studies must accomplish 
the following criteria: to be clinical trials in humans, to 
present a true control group, to show the results of the 
outcomes at the baseline and at the end of the trial, and to 
indicate the standard deviation (SD) of the measurements. 
Data extraction and synthesis
After the selection of the studies, the clinical trials 
included were carefully analyzed and the following data 
were extracted and summarized: first author’s last name, 
year of publication, location, study design, number of 
patients (intervention and control groups), type of patients, 
mean age and gender of patients, study duration, dosage 
of I. paraguariensis and the list of outcomes of interest. 
According to the PRISMA methodology (Moher et al., 
2015), two authors independently reviewed and extracted 
the data using a prespecified protocol. In cases of 
discordance, a third reviewer was consulted to analyse 
discrepancies in data extraction.
Risk of bias assessment
The risk of publication bias of each included study 
was assessed using the “Cochrane Guide for Review 
Authors on Assessing Study Quality” which is based on 
“Cochrane Collaboration’s tool for assessing risk of bias” 
(Ryan et al., 2013). This tool classifies the risk of bias in 
randomized controlled trials (RCTs) included in reviews 
as “High risk”, “Unclear” or “Low risk” in accordance 
with 7 domains: random sequence generation, allocation 
concealment, blinding of participants and personnel, 
blinding of outcome assessment, incomplete outcome data, 
selective reporting and other sources of bias (Higgins et al., 
2011). This classification was independently assigned by 
two authors and discrepancies in assessment were resolved 
through discussions between the authors or by consultation 
of a third investigator. The results of the risk of bias 
assessment are presented in a risk of bias summary and in a 
risk of bias graph, which were sketched using the software 
Review Manager 5.3 (Version 5.3.5).
Statistical analyses
For each outcome of interest, an assessment was 
performed on the pooled effect of the different interventions 
in terms of weighted mean differences (WMD) between the 
change from baseline and post-treatment mean values. Data 
statistical analysis was performed using Comprehensive 
Meta-Analysis software (Version 2.0) by introducing the 
number of patients, the differences in mean and respective 
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SD values of the outcomes for intervention and control 
groups. Forest plots were generated to illustrate the study-
specific effect sizes along with a 95% confidence interval 
(CI). The random effects model was used, however, when 
a fixed effects model would be more useful, i.e., when there 
was little variance in effect sizes, the software automatically 
converted the random effects model into a fixed effects 
model (Borenstein, Hedges, Higgins, 2009). The statistic I2 
of Higgins was used as a measure of inconsistency across 
the findings of the included studies. The scale of I2 has a 
range of 0 to 100% and values on the order of 25%, 50% and 
75% are considered low, moderate and high heterogeneity, 
respectively (Higgins et al., 2003). Three different analyses 
were used to assess the potential impact of publication bias 
on the present meta-analysis. The first analysis is a funnel 
plot (Light, Singer, Willett, 1994; Light, Pillemer, 1984). 
The symmetry of the funnel plots in which mean differences 
were plotted against their corresponding standard error (SE) 
was assessed. In the absence of publication bias, the studies 
were symmetrically distributed in relation to the pooled 
effect size. Given that the interpretation of a funnel plot is 
largely subjective, Egger’s regression test was performed 
to test for potential publication bias (Egger et al., 1997). 
Since this test tends to have lower power, the absence of 
a significant correlation cannot be taken as evidence of 
symmetry (Borenstein, Hedges, Higgins, 2009). Therefore, 
another analysis was used based on the approach of Duval 
and Tweedie’s Trim and Fill (Duval, Tweedie, 2000a; 
2000b). Trim and Fill uses an iterative procedure to remove 
studies that contain a small sample size from the positive 
(or negative) side of the funnel plot. It then re-computes 
the effect size at each iteration until the funnel plot is 
symmetrical in terms of the new effect size, yielding an 
unbiased estimate of the pooled effect size. This approach 
allows the best estimate of the unbiased pooled effect size to 
be obtained and lends itself an intuitive visual display as it 
creates a funnel plot that includes both the observed studies 
and the imputed studies. 
The sensitivity analysis was also performed by 
removing each study, one at a time, to evaluate the stability 
of the results. 
Meta-regression analysis was also undertaken to 
evaluate the association between calculated WMD in body 
weight, body mass index (BMI) and waist circumference, 
and the study duration (Borenstein, Hedges, Higgins, 
2009).
Trial Sequential Analysis
TSA is a methodology that uses a combination of 
techniques in which the evidence required is quantified, 
providing a value for the required information size (RIS) 
(Thorlund et al., 2011). The TSA program version 0.9.5.5 
Beta (Copenhagen Trial Unit, www.ctu.dk/tsa/downloads/
aspx) was used to adjust the confidence intervals 
due to sparse data and repeated testing in cumulative 
meta-analysis. If the cumulative Z-curve crosses a trial 
sequential monitoring boundary or enters the futility 
area, then it can be concluded that a sufficient level of 
evidence for the anticipated intervention effect may have 
been reached and no further trials are needed; whereas if 
the Z-curve does not cross any of the boundaries and the 
RIS has not been reached, there is insufficient evidence to 
reach a conclusion. The outcome variables in the present 
meta-analysis were continuous, so the RIS was estimated 
based on the empirical data auto-generated by the software 
per the data input. The TSA was performed at the level 
of an overall 5% risk of type I error and a power of 20%. 
RESULTS AND DISCUSSION
Search and selection of studies
The progression details of the electronic search for 
this systematic review are represented as a flow-diagram 
(Figure 1). From the 153 eligible articles, 8 were included 
in this systematic review with meta-analysis. Among the 
reasons for exclusion of articles were mostly the lack of 
a true control group and the absence of SD values for the 
outcomes of interest. The work of Kim et al. (2012) was 
divided into 2 different trials because the authors used 
two durations for the intervention (3 and 6-weeks). A 
similar procedure was undertaken in the trial of Kim et al. 
(2015) (6 and 12-weeks). The study of Klein et al. (2011) 
was divided into 6 different trials taking the possible 
combinations between the study duration (20, 40 and 
60-days) and the type of patients enrolled in the trial 
(type 2 diabetes and pre-diabetes) into account. The work 
of Morais et al. (2009) was divided into 8 different trials, 
considering the different durations of the study (20, 40, 60 
and 90-days) along with the treatment of the dyslipidemic 
patients with or without statin. As a result, a total of 
22 clinical trials were considered for the quantitative 
synthesis of the data, totalizing 726 patients enrolled.
Included studies and trials characteristics
The main characteristics of the included trials are 
summarized in the Table I. The studies cover almost a 
decade, from 2007 to 2016. The included trials were mostly 
performed in Brazil and in the Republic of Korea. It will 
be important to evaluate the effects of I. paraguariensis 
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consumption on patients from other countries, as several 
other factors may interfere in the biological effects 
when consuming polyphenol-rich plants. For example, 
the bioavailability of the bioactive compounds, and 
particularly the polyphenols, is extremely affected by their 
metabolization, which in turn is influenced by the genotype 
characteristics of a certain region of the world (Rein et al., 
2013). The patients subjected to the intervention with 
I. paraguariensis were mainly dyslipidemic, obese and 
diabetic. However, it will be necessary to evaluate the 
effects of I. paraguariensis also in healthy volunteers 
due to the high concentrations of caffeine found in this 
plant. I. paraguariensis was administered to the patients 
mainly by aqueous preparations, varying the duration of 
the interventions and the dosage. 
Risk of publication bias
The results found in the assessment of the risk 
of publication bias from the included studies are 
summarized in Figure 2. The studies of Morais et al. 
(2009) (from A to H) and Salerno (2007) were non-
randomized and for that reason were not classified to their 
risk of bias since the Cochrane’s tool can only be applied 
to RCTs. In general, all the trials satisfied the 7 domains 
of bias defined by Cochrane Collaboration. The included 
RCTs claimed to be randomized, but only 6 trials detailed 
the randomization process and so were classified as 
“Low risk” in the random sequence generation domain. 
Concerning the performance and detection bias, related 
to blinding of participants and personnel, and blinding of 
outcome assessment, respectively, there were 2 studies 
(Boaventura et al., (2012), and Pontin (2010)) classified 
as “High risk”, since there were doubts regarding the 
blinding process (single or double). It is important to 
note, however, that the assessment of risk of publication 
bias is a subjective task, even when employing the 
Cochrane’s tool, because it is based on the personal 
judgments of the review authors.
FIGURE 1 - Flow-diagram of database search, trial selection and articles included in this meta-analysis. *The works of Kim et al., 
2012 and Kim et al., 2015 were divided into 2 different trials. The work of Klein et al., 2011 was divided into 6 different trials. The 
work of Morais et al., 2009 was divided into 8 different trials.
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Effects of I. paraguariensis consumption on 
anthropometric measurements, lipid profile and 
blood pressure
Several previous reports have suggested that 
I. paraguariensis may possess anti-obesity properties, 
together with the potential to ameliorate the blood 
lipid profile of patients (Boaventura et al., 2012; 
Gambero, Ribeiro, 2015; Kim et al., 2015). In contrast, 
I. paraguariensis consumption may cause an increase in 
blood pressure due to the high concentration in caffeine 
(Cardozo Junior, Morand, 2016; Pontilho et al., 2015). 
In this sense, the outcomes considered in this meta-
analysis include some anthropometric measurements 
(body weight, BMI, and waist circumference), lipid 
profile and blood pressure of the participants in the 
clinical trials.
The lipid profile comprises the total cholesterol 
(TC), triglycerides (TG), HDL-cholesterol (HDL) and 
LDL-cholesterol (LDL). In the case of the blood pressure, 
the values of systolic blood pressure (SBP) and diastolic 
blood pressure (DBP) were both considered in the 
statistical analysis.
Figure 3 represents the forest plots resulting from 
the meta-analysis for the considered outcomes. Table 
II summarizes the meta-analysis results. Overall, it is 
possible to verify that I. paraguariensis consumption 
significantly reduces the body weight (Figure 3A) (WMD: 
-0.521 kg; 95% CI: -0.870 to -0.172; p-value= 0.003) and 
consequently the BMI (Figure 3B) of patients (WMD: 
-0.208 kg/m2; 95% CI: -0.342 to -0.073; p-value= 0.002), 
which together with the significant reduction of waist 
circumference (Figure 3C) (WMD: -0.668 cm; 95% CI: 
-1.316 to -0.021; p -value= 0.043) demonstrate that, in 
fact, I. paraguariensis has some potential to treat obesity, 
which is in agreement with the findings of some clinical 
trials included in the present meta-analysis. It should be 
noted that no heterogeneity (I2=0%) was observed among 
the trials for these outcomes (Table II). Concerning the 
results of TSA, it is possible to conclude by the visual 
inspection of the plots (Figure 4), that, in general, the 
cumulative Z-curve crosses the conventional significance 
test boundary and RIS-adjusted boundary value, 
indicating that the evidence needed to reach a conclusion 
was sufficient and no further trials were needed; thus, 
additional trials are not required and are unlikely to alter 
FIGURE 2 - Results of risk of bias assessment regarding the methodological quality of included studies: A) Risk of bias summary: 
review author’s judgments about each risk of bias item for each included study; B) Risk of bias graph: review author’s judgments 
about each risk of bias item presented as percentages across all included studies.
A. F. S. Luís, F. C. Domingues, L. M. J. P. Amaral
Braz. J. Pharm. Sci. 2019;55:e17615Page 8 / 15
the conclusions obtained in the present work in what 
concerns the anthropometric measurements.
Regarding the remaining outcomes under analysis, 
it was verified that I. paraguariensis have no significant 
implications in both the lipid profile (Figures 3D, 3E, 
3F, 3G and Table II) and blood pressure of patients 
(Figures 3H, 3I and Table II). However, the number of 
clinical trials evaluating the effects of I. paraguariensis in 
these outcomes is reduced, leading to some heterogeneity 
(Table II) in addition to extremely high values of RIS 
(Table II), not being reached, indicating that more clinical 
trials are needed in order to achieve sufficient evidence to 
reach a conclusion. 
Moreover, the TSA program was not able to produce 
the plots for the remaining outcomes due to the scarcity 
of data.
FIGURE 3 - Forest plots of comparisons of the effects I. paraguariensis consumption on the outcomes of this meta-analysis, 
compared with control arms. BMI – body mass index; DBP – diastolic blood pressure; HDL – HDL-cholesterol; LDL – LDL-
cholesterol; SBP – systolic blood pressure; TC – total cholesterol; TG – triglycerides.
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The sensitivity analysis was also performed by 
excluding one or more studies from the analysis to see how 
this affected the results. The results showed that the pooled 
effects of I. paraguariensis consumption on the considered 
outcomes did not change substantially if a single or a few 
studies were omitted (data not shown). 
Overall, the sensitivity analysis demonstrated 
that the findings of this meta-analysis on the considered 
outcomes are robust.
During this systematic review, it was verified 
that I. paraguariensis was administered to the patients 
at different intervention durations. Therefore, a meta-
regression analysis (Figure 5) was conducted to evaluate 
the association between changes in body weight, 
BMI and waist circumference, and the study duration. 
The results of meta-regression suggest no significant 
correlation between the intervention duration and body 
weight (Figure 5A; p-value= 0.0896), BMI (Figure 5B; 
p-value= 0.105) or waist circumference (Figure 5C; 
p-value= 0.125). 
In summary, the findings clearly showed that the 
use of I. paraguariensis might be useful against obesity.
In the previous comprehensive reviews published 
by Bracesco et al., 2011 and by Gambero and Ribeiro, 
2015, some possible mechanisms of action, regarding the 
anti-obesity potential of I. paraguariensis, were addressed; 
however, more studies at cellular and molecular level must 
be undertaken to better understand this biological activity 
of I. paraguariensis.
Publication bias
To analyse the publication bias, funnel plots were 
generated for the defined outcomes considering the Trim 
and Fill adjustment (Figure 6). These funnel plots included 
both the observed studies (shown as blue circles) and the 
necessary imputed studies (shown as red filled circles) to 
obtain the absence of bias. It was observed that there is 
an absence of bias for body weight (Figure 6 A). For the 
remaining outcomes, some studies are imputed on the 
FIGURE 3 (cont.) - Forest plots of comparisons of the effects I. paraguariensis consumption on the outcomes of this meta-analysis, 
compared with control arms. BMI – body mass index; DBP – diastolic blood pressure; HDL – HDL-cholesterol; LDL – LDL-
cholesterol; SBP – systolic blood pressure; TC – total cholesterol; TG – triglycerides.
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TABLE II - Meta-analysis results of the effects of I. paraguariensis consumption on the considered outcomes
Outcomes Results Number of trials 95% CI p-value I2 (%) RIS
Body Weight
Total 20 - - - 579
WMD observed - -0.521 (-0.870; -0.172) 0.003* 0
WMD adjusted - -0.521 (-0.870; -0.170) - -
BMI
Total 19 - - - 499
WMD observed - -0.208 (-0.342; -0.073) 0.002* 0
WMD adjusted - -0.209 (-0.343; -0.075) - -
Waist Circumference
Total 19 - - - 973
WMD observed - -0.668 (-1.316; -0.021) 0.043* 0
WMD adjusted - -0.504 (-1.127; 0.119) - -
TG
Total 10 - - - 2334
WMD observed - -5.895 (-14.293; 2.503) 0.169 0
WMD adjusted - -1.249 (-9.540; 7.042) - -
TC
Total 21 - - - 19353
WMD observed - -1.305 (-5.670; 3.599) 0.662 3.869
WMD adjusted - -0.001 (-4.849; 4.829) - -
HDL
Total 19 - - - 64545
WMD observed - 0.341 (-0.808; 1.490) 0.560 0
WMD adjusted - 0.341 (-0.808; 1.490) - -
LDL
Total 18 - - - 1436902
WMD observed - -0.371 (-5.685; 4.944) 0.891 33.670
WMD adjusted - 1.274 (-4.369; 6.918) - -
SBP
Total 15 - - - 4561
WMD observed - 1.340 (-1.667; 4.346) 0.382 23.509
WMD adjusted - 2.621 (-0.725; 5.966) - -
DBP
Total 15 - - - 2421
WMD observed - 1.252 (-1.008; 3.512) 0.278 0
WMD adjusted - 1.252 (-1.008; 3.512) - -
BMI – body mass index; CI – confidence interval; DBP – diastolic blood pressure; HDL – HDL-cholesterol; LDL – LDL-
cholesterol; RIS – required information size; SBP – systolic blood pressure; TC – total cholesterol; TG – triglycerides; WMD 
– weighted mean differences; * - indicates a significant result.
right or on the left size to “adjust” the funnel plots for 
the absence of publication bias. Therefore, by observing 
the funnel plots, it is possible to verify that publication 
bias cannot be completely excluded. The values of WMD 
adjusted for the outcomes under analysis are presented in 
Table II.
In addition to the visual inspection of the funnel 
plots, the presence of publication bias was explored using 
Egger’s regression test. This test did not indicate evidence 
of publication bias for the impact of I. paraguariensis 
consumption on the evaluated outcomes (Table III).
CONCLUSIONS
In conclusion, this systematic review with meta-
analysis and TSA of clinical trials, demonstrated the 
positive effects of I. paraguariensis consumption 
on the reduction of body weight, BMI, and waist 
circumference of patients, showing its anti-obesity 
potential. However, special attention must be given 
due to the high concentrations of caffeine found in this 
plant. Future clinical trials should evaluate the effects of 
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FIGURE 4 - Trial Sequential Analysis (TSA) on pooled 
results of the effects of I. paraguariensis consumption on the 
anthropometric measurements considered in this meta-analysis.
FIGURE 5 - Meta-regression plots of the association between 
calculated weighted mean differences (WMD) in body weight, 
body mass index (BMI) and waist circumference, and the study 
duration.
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TABLE III - Assessment of publication bias for the impact of I. paraguariensis consumption on the considered outcomes
Outcomes
Egger’s regression test
95% CI t df p-value
Body weight -0.650; 0.130 1.390 18 0.182
BMI -0.655; 0.231 1.013 16 0.326
Waist circumference -0.824; 0.151 1.455 17 0.164
TG -2.126; 0.135 1.857 17 0.080
TC -2.161; 1.063 0.712 19 0.485
HDL -1.460; 2.233 0.441 17 0.664
LDL -3.015; 0.975 1.084 16 0.295
SBP -2.537; 0.574 1.360 13 0.196
DBP -3.930; 3.630 0.086 13 0.933
BMI – body mass index; CI – confidence interval; DBP – diastolic blood pressure; df – degrees of freedom; HDL – HDL-cholesterol; 
LDL – LDL-cholesterol; SBP – systolic blood pressure; TC – total cholesterol; TG – triglycerides.
FIGURE 6 - Funnel plots of standard error by difference in means (publication bias tests) of the effects of I. paraguariensis 
consumption on the outcomes of this meta-analysis. BMI – body mass index; DBP – diastolic blood pressure; HDL – HDL-
cholesterol; LDL – LDL-cholesterol; SBP – systolic blood pressure; TC – total cholesterol; TG – triglycerides.
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FIGURE 6 (cont.) - Funnel plots of standard error by difference in means (publication bias tests) of the effects of I. paraguariensis 
consumption on the outcomes of this meta-analysis. BMI – body mass index; DBP – diastolic blood pressure; HDL – HDL-
cholesterol; LDL – LDL-cholesterol; SBP – systolic blood pressure; TC – total cholesterol; TG – triglycerides.
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I. paraguariensis on lipid profile and blood pressure of 
patients, together with the evaluation of its consumption 
by healthy people.
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